TrialBMC cancer2021

Randomized phase II study of SOX+B-mab versus SOX+C-mab in patients with previously untreated recurrent advanced colorectal cancer with wild-type KRAS (MCSGO-1107 study).

Yujiro Nishizawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.